The purpose of this study is to evaluate the safety and effectiveness of an investigational hydrocortisone acetate 90 mg suppository formulation administered with the Sephure® applicator for the treatment of moderate to severe ulcerative colitis of the rectum.
People included in the study will have study-related health monitoring at no cost and will be provided with a randomly assigned study drug kit. Participation includes as few as 39 days and at most, 54 days, at least 6 study site visits and 2 telephone calls.
The DAP-CORONA RCT is a phase III randomized, triple-blind, placebo-controlled multi-center study on the efficacy and safety of Dapsone in adult patients who have been presenting with symptoms, have been diagnosed with COVID-19 infection and are at high risk of developing complications and requiring hospitalization. Approximately 3 000 individuals who meet the eligibility criteria of this trial will be selected to receive either Dapsone, a generic drug, or placebo tablets for 21 days on a random basis.
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 and 20
mg Compared to Placebo for Relief of Heartburn in Subjects with Symptomatic Non-Erosive Gastroesophageal Reflux
Disease (NERD) After 4 Weeks and to Evaluate the Efficacy and Safety of Vonoprazan 10 and 20 mg for Relief of Heartburn in Subjects with NERD After 6 Months
DO YOU SUFFER FROM SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE? A CLINICAL TRIAL MIGHT BE AN OPTION FOR YOU!
The purpose of this study, which involves research, is to determine whether the investigational drug, vonoprazan, is safe and effective in the potential treatment of symptomatic non-erosive gastroesophageal reflux disease compared to a placebo.
HOW DO I KNOW IF I QUALIFY TO PARTICIPATE?
You might quality to participate if you have been experiencing frequent heartburn over the Iast six months. You must be at least 18 years old and will need to meet with a physician who is participating in this study to determine if you are fully eligible and if this study is right for you.
HOW LONG DOES THIS STUDY LAST AND WHAT WILL I HAVE TO DO?
If you decide to participate in this study, you will be asked to attend a total of 10 study visits (6 in person at study location and 4 phone call contacts) over 33 weeks. Your study physician will provide you with the study drug, which could contain either active treatment or placebo, and perform assessments to track your overall health and progress throughout the study.
The cycle of chronic hives, also called chronic urticaria, may seem like it occupies every part of life. When the itching and pain keep coming back, it can feel like a never-ending struggle, even with treatment. We are conducting a trial for people who have different types of chronic uncontrolled urticaria.
There are 2 types of chronic urticaria (hives):
Chronic inducible urticaria (CINDU)
A person living with chronic inducible urticaria typically knows what triggers their flares. These triggers can include: Pressure, Heat, Cold, such as cold water or wind, Exercise, Increase in body, temperature, Contact with water sun exposure.
Chronic spontaneous urticaria (CSU)
A person living with chronic spontaneous urticaria, also called chronic idiopathic urticaria, does not have a trigger for their flares.
The Red-C 3131 Study At-a-Glance
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation in Cirrhosis
The Red-C 3131 Study is a phase 3 study to evaluate the efficacy and safety of rifaximin SSD-40IR in delaying hepatic encephalopathy (HE)-related hospitalizations in patients with advanced liver cirrhosis. About 466 patients will be enrolled across 100 sites.
About the Study Medicine
The study medicine, rifaximin, is currently FDA approved to treat diarrhea from irritable bowel syndrome, traveler’s diarrhea and others. It has been prescribed off-label to treat HE.
The mode of action of antibiotics for the treatment of HE is to reduce the number of deaminating bacteria and urease-producing bacteria, thereby reducing the production of ammonia and other potential toxins.
Eligible patients will receive the following at no cost:
The study medicine
Study-related medical care
Reasonable study-related travel expenses may be included